Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.12 +4.4%	$2.27	$0.40 ▼ $3.10	$334.77M	2.13	3.68 million shs	6.09 million shs
EDIT Editas Medicine	$2.80 +2.6%	$2.63	$0.91 ▼ $4.12	$245.48M	2.19	2.07 million shs	1.46 million shs
ROIV Roivant Sciences	$11.92 +0.9%	$11.43	$8.73 ▼ $13.06	$8.03B	1.15	4.41 million shs	4.90 million shs
SRPT Sarepta Therapeutics	$20.22 +0.8%	$17.99	$10.41 ▼ $143.49	$1.96B	0.46	16.05 million shs	9.52 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	+3.05%	+15.34%	-15.06%	-8.97%	+59.84%
EDIT Editas Medicine	+2.25%	-7.77%	-18.75%	+76.13%	-33.09%
ROIV Roivant Sciences	+0.77%	+0.51%	+2.70%	+8.65%	+0.17%
SRPT Sarepta Therapeutics	-2.53%	-1.18%	+47.39%	-47.07%	-86.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTMX CytomX Therapeutics	4.0795 of 5 stars	3.5	1.0	4.7	1.5	1.7	1.3
EDIT Editas Medicine	4.2446 of 5 stars	3.1	4.0	4.3	1.5	2.5	0.6
ROIV Roivant Sciences	3.4721 of 5 stars	3.6	3.0	0.0	4.2	3.3	0.0
SRPT Sarepta Therapeutics	4.6432 of 5 stars	4.0	2.0	4.2	2.4	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	3.00	Buy	$5.75	171.23% Upside
EDIT Editas Medicine	2.23	Hold	$5.10	82.14% Upside
ROIV Roivant Sciences	3.25	Buy	$16.50	38.42% Upside
SRPT Sarepta Therapeutics	2.07	Hold	$43.50	115.13% Upside

Current Analyst Ratings Breakdown

Latest SRPT, CTMX, EDIT, and ROIV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	SRPT Sarepta Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$17.00
8/15/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$3.00 ➝ $5.00
8/15/2025	SRPT Sarepta Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$12.00
8/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $6.00
8/7/2025	SRPT Sarepta Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$19.00
8/7/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$48.00 ➝ $50.00
7/31/2025	CTMX CytomX Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
7/29/2025	SRPT Sarepta Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$22.00
7/29/2025	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
7/29/2025	SRPT Sarepta Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Perform ➝ Market Perform	$25.00 ➝ $50.00
7/29/2025	SRPT Sarepta Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $20.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$141.10M	2.48	$0.39 per share	5.44	$0.73 per share	2.90
EDIT Editas Medicine	$38.90M	6.47	N/A	N/A	$0.21 per share	13.33
ROIV Roivant Sciences	$29.05M	278.94	N/A	N/A	$7.08 per share	1.68
SRPT Sarepta Therapeutics	$1.90B	1.04	$2.39 per share	8.45	$13.89 per share	1.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	$31.87M	$0.56	3.79	N/A	N/A	34.04%	158.70%	36.04%	11/6/2025 (Estimated)
EDIT Editas Medicine	-$237.09M	-$2.85	N/A	N/A	N/A	-608.88%	-200.25%	-68.57%	11/3/2025 (Estimated)
ROIV Roivant Sciences	-$171.98M	-$0.70	N/A	N/A	N/A	-2,111.79%	-15.90%	-14.95%	N/A
SRPT Sarepta Therapeutics	$235.24M	-$0.87	N/A	1.85	N/A	-2.34%	-1.03%	-0.37%	11/5/2025 (Estimated)

Latest SRPT, CTMX, EDIT, and ROIV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	EDIT Editas Medicine	-$0.41	-$0.63	-$0.22	-$0.63	$1.81 million	$3.58 million
8/6/2025	Q2 2025	SRPT Sarepta Therapeutics	$0.89	$2.02	+$1.13	$1.89	$530.66 million	$611.09 million
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	4.20	4.20
EDIT Editas Medicine	N/A	2.77	2.77
ROIV Roivant Sciences	N/A	40.54	40.54
SRPT Sarepta Therapeutics	0.84	2.89	1.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
EDIT Editas Medicine	71.90%
ROIV Roivant Sciences	64.76%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	6.60%
EDIT Editas Medicine	2.10%
ROIV Roivant Sciences	10.80%
SRPT Sarepta Therapeutics	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	164.91 million	154.03 million	Optionable
EDIT Editas Medicine	230	89.92 million	88.03 million	Optionable
ROIV Roivant Sciences	860	679.81 million	606.39 million	Optionable
SRPT Sarepta Therapeutics	1,372	97.71 million	90.29 million	Optionable

SRPT, CTMX, EDIT, and ROIV Headlines

Recent News About These Companies

Levi & Korsinsky Reminds Sarepta Therapeutics, Inc. Investors of the Pending Class Action ...

1 hour ago | reflector.comR

Levi & Korsinsky Reminds Sarepta Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 – SRPT

August 22 at 4:30 PM | globenewswire.com

SRPT Deadline: SRPT Investors with Losses in Excess of $100K Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit

August 22 at 2:49 PM | prnewswire.com

INVESTOR DEADLINE MONDAY: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPT

August 22 at 2:00 PM | prnewswire.com

Sarepta Therapeutics: A Strong Opportunity Amidst The Panic

August 22 at 12:50 PM | seekingalpha.com

SRPT 3-DAY DEADLINE ALERT: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline

August 22 at 11:46 AM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT

August 22 at 10:00 AM | prnewswire.com

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Expected to Rise, Bank of America Analyst Says

August 22 at 9:07 AM | marketbeat.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Short Interest Update

August 22 at 6:40 AM | marketbeat.com

Bank of America Increases Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $17.00

August 22 at 2:40 AM | americanbankingnews.com

SRPT FINAL DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 25 Deadline in Securities Class Action – SRPT

August 21 at 9:19 PM | globenewswire.com

INVESTOR DEADLINE AUGUST 25: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPT

August 21 at 4:30 PM | prnewswire.com

Sarepta: A Dizzying Pivot From Gene Therapy Peril To An RNA Future (Rating Downgrade)

August 21 at 4:26 PM | seekingalpha.com

SAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Before the August 25th Deadline

August 21 at 4:04 PM | globenewswire.com

Sarepta Therapeutics (SRPT): B of A Securities Lowers Price Target | SRPT Stock News

August 21 at 3:31 PM | gurufocus.com

Sarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – SRPT

August 21 at 3:07 PM | globenewswire.com

Sarepta Therapeutics stock falls after refinancing convertible notes

August 21 at 12:44 PM | za.investing.com

Sarepta Therapeutics shares dip after convertible note refinancing

August 21 at 12:44 PM | msn.com

Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027

August 21 at 12:44 PM | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT

August 21 at 10:32 AM | globenewswire.com

Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) - August 25, 2025 Deadline to Join - Contact The Gross Law Firm

August 21 at 8:45 AM | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SRPT, CTMX, EDIT, and ROIV Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$2.12 +0.09 (+4.43%)

Closing price 04:00 PM Eastern

Extended Trading

$2.10 -0.02 (-0.94%)

As of 07:42 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Editas Medicine NASDAQ:EDIT

$2.80 +0.07 (+2.56%)

Closing price 04:00 PM Eastern

Extended Trading

$2.80 +0.01 (+0.18%)

As of 07:51 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Roivant Sciences NASDAQ:ROIV

$11.92 +0.11 (+0.93%)

Closing price 04:00 PM Eastern

Extended Trading

$11.78 -0.14 (-1.17%)

As of 07:34 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Sarepta Therapeutics NASDAQ:SRPT

$20.22 +0.16 (+0.80%)

Closing price 04:00 PM Eastern

Extended Trading

$20.18 -0.04 (-0.22%)

As of 07:59 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time